Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are we at $10-$20 yet.
It seems JBEM changed the name.
Now I understand why the Doc tries to avoid talking about pro-140. To me, FDA reduces the PIII patient number from 300 to 150 is a Hugh deal!!! This shows FDA has seen the results so far for PIIb and they are convinced by the results and do as much as they could to help CYDY to speed up their PIII combination trial.
Yes. Seems to me, the Doc is trying to avoid talking about Pro-140 as much as he could. Not sure why?
Somebody is dumping today??
I feel the same. He was pumping CYDY right before ASM, like no tomorrow!! Like it would go to the moon!! Now what, the change just incredible!!
What? So now you are bashing, not more pumping? It's still at 1.1$! Where did you see .90?
Well. It did help JBEM and his boys! From .90 to 1.40, that's a very decent gain for JBEM and his boys. But at the mean time left a lot of bag holders too waiting for the next pump and dump. Hope there is one!!!
More 200 patients have been enrolled in the MONO therapy so far. That sounds good to me!!
Thank you for the info on this Dr. I was just posting purely from the web for comments.
What do you think about this perspective by
Daniel R. Kuritzkes, MD
Professor of medicine, Harvard Medical School
Physician and chief of the division of infectious diseases,
Brigham and Women’s Hospital
"I think these data are really very preliminary. In my mind, they do not really tell us much about how the drug might be used. There are lots of therapies that might be used to maintain suppression once people are suppressed on a triple-drug regimen — protease monotherapy, integrase inhibitor monotherapy, etc. There may be a small number of patients who would want to get weekly injections in order to avoid having to take daily pills. However, I think that PRO 140 being limited to CCR5 virus is an another issue, and there is some concern whether people might relapse over time. It is an intriguing result, but this a small subset of a larger study, and I think we just need more data."
Somebody just 5000 Sh @$1.38. So no dumping today. Hope the upward move continues......
Top Penny, it was a very strong day for iBio both price and volume. Very excited. Hope to see some news from the company!
I think if PRO 140 succeeds in PIII, then 30 times is very possible. Time will tell. Hope we all get rewarded Hugh!!!
I think nobody likes delay on data and plus Culley's past track record doesn't seem good. But I hope this time, the data will be EPIC!!
Thank you!
I really like your numbers. No doubt. But want to be cautious as all these are based on a high if, that is if the drugs are successful and make them to the market.
Need consider the future dilutions to fund the trials. To me dilution has more chance than BP partner. But in the end, we will still have gains, but not 100x. Maybe 10x?
You need to count dilutions which are highly likely based on the costs of the trials.
You mean 5-10 years away. That's a loooong wait!!
I think he means 2 to 15 (3 x 5). Am I in your direction or the opposite?
All dreaming. Not bad though.
Thank you for the info! I am kinda new to iBio and have accumulated a few 10k so far. I have got time to wait.
So you are still bullish and confident on iBio. I am holding a big chunk too and hope to win big at the end. What is your time frame on this. Thanks.
Did you see the first paragraph from the PR about Saturday's conference?
"NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease."
I think technical is ALWAYS right. If not, it is either a break up or break down. So TA is ALWAYS RIGHT.
Are you kidding? They didn't even reply to FDA's questions!!!